Videos

1 expert is featured in this series

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, explains the significance of OrigAMI-5's all-comer design, which enrolls patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) regardless of PD-L1 combined positive score (CPS), using local CPS testing only for stratification rather than eligibility.

1 expert is featured in this series

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses the rationale for the phase 3 OrigAMI-5 study, which evaluates amivantamab earlier, in the first-line setting, in combination with pembrolizumab and carboplatin.